Search research articles
Contact Us
Filters
Showing results (71-80 of 531) with videos related to
Page
of 54
Sort By:
Pharmacotherapy
|
July 26, 2006
Tigecycline: first of a new class of antimicrobial agents
Warren E Rose, Michael J Rybak
American Journal of Hospital Pharmacy
|
February 15, 1994
Cefepime: part of the new generation
M J Rybak, S M Palmer
Diagnostic Microbiology and Infectious Disease
|
December 22, 2005
Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin
Brian T Tsuji, Michael J Rybak
Antimicrobial Agents and Chemotherapy
|
November 13, 2013
Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic model
Brian J Werth, Michael J Rybak
Clinical Pharmacy
|
February 1, 1986
Aminoglycoside pharmacokinetics in patients with spinal cord injury
V Tutag-Lehr, M J Rybak
DICP : the Annals of Pharmacotherapy
|
November 1, 1989
Ofloxacin: a review
M A Smythe, M J Rybak
Antimicrobial Agents and Chemotherapy
|
February 22, 2001
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model
E A Coyle, M J Rybak
Antimicrobial Agents and Chemotherapy
|
February 13, 2001
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations
R L Akins, M J Rybak
Drugs
|
February 24, 2001
Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options
M J Rybak, R L Akins
Antimicrobial Agents and Chemotherapy
|
March 1, 1996
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots
S M Palmer, M J Rybak
Page
of 54
Search research articles
Search
Showing results (71-80 of 531) with videos related to
Sort By:
Page
of 54
Pharmacotherapy
|
July 26, 2006
Tigecycline: first of a new class of antimicrobial agents
Warren E Rose, Michael J Rybak
American Journal of Hospital Pharmacy
|
February 15, 1994
Cefepime: part of the new generation
M J Rybak, S M Palmer
Diagnostic Microbiology and Infectious Disease
|
December 22, 2005
Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin
Brian T Tsuji, Michael J Rybak
Antimicrobial Agents and Chemotherapy
|
November 13, 2013
Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic model
Brian J Werth, Michael J Rybak
Clinical Pharmacy
|
February 1, 1986
Aminoglycoside pharmacokinetics in patients with spinal cord injury
V Tutag-Lehr, M J Rybak
DICP : the Annals of Pharmacotherapy
|
November 1, 1989
Ofloxacin: a review
M A Smythe, M J Rybak
Antimicrobial Agents and Chemotherapy
|
February 22, 2001
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model
E A Coyle, M J Rybak
Antimicrobial Agents and Chemotherapy
|
February 13, 2001
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations
R L Akins, M J Rybak
Drugs
|
February 24, 2001
Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options
M J Rybak, R L Akins
Antimicrobial Agents and Chemotherapy
|
March 1, 1996
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots
S M Palmer, M J Rybak
Page
of 54